Precigen, Inc. Overview
Pro stress-test →Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The company has strategically narrowed its focus toward commercialization of its lead asset PRGN-2012, a gene therapy for recurrent respiratory papillomatosis (RRP).
Strategic Profile
Pro stress-test →In August 2024, Precigen announced a strategic reprioritization of its clinical portfolio and workforce reduction of over 20% to focus on potential commercialization of PRGN-2012. The company is pursuing pre-commercialization efforts including submission of a rolling biologics license application under an accelerated approval pathway, conducting confirmatory clinical trials, and manufacturing of commercial product.
Competitive Landscape
Pro stress-test →Precigen competes in the gene therapy and cell therapy space against established players like Bluebird Bio and Gilead Sciences, as well as emerging biotech firms developing comparable modalities. The company's focus on RRP and proprietary AdenoVerse platform differentiate its positioning, though the broader gene therapy market faces regulatory and manufacturing complexity. Most direct competition in RRP treatment comes from conventional surgical and ablative approaches rather than gene therapy alternatives.
Industry Context
Precigen, Inc. operates in Biotechnology / Biopharmaceuticals.
Key facts
Founded: 1998 · Headquarters: Germantown, Maryland · Employees: 143